---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-024258"
form_type: "8-K"
ticker: "DYN"
cik: "0001818794"
company_name: "Dyne Therapeutics, Inc."
filed_at: "2023-05-25T23:59:59+00:00"
generated_at: "2026-06-14T14:53:08.514152+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Dyne Therapeutics director Lawrence Klein resigns; shareholders elect new directors and ratify auditor

## Summary
- Dr. Lawrence Klein resigned from Dyne Therapeutics board effective May 24, 2023, citing no disagreement with the company.
- Stockholders elected Joshua Brumm, David Lubner, and Jason Rhodes as Class III directors for three-year terms.
- Joshua Brumm received 35,497,922 votes for election; David Lubner received 32,530,452; Jason Rhodes received 28,522,828.
- Shareholders ratified Deloitte & Touche as independent auditor for fiscal year 2023 with 44,199,721 votes for, 2,413 against.

## SEC filing metadata
- accession: 0000950170-23-024258
- form_type: 8-K
- ticker: DYN
- cik: 0001818794
- company_name: Dyne Therapeutics, Inc.
- filed_at: 2023-05-25T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818794/000095017023024258/0000950170-23-024258-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818794/000095017023024258/dyn-20230524.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-024258
- JSON: https://secwatch.observer/filing/0000950170-23-024258.json
- Plain text: https://secwatch.observer/filing/0000950170-23-024258.txt

## Key facts
- Executive change
  Dr. Lawrence Klein resigned as member of the Board of Directors at Dyne Therapeutics, Inc..
  - Action: resigned
  - Role: member of the Board of Directors
  source text: On May 24, 2023, Dr. Lawrence Klein notified Dyne Therapeutics, Inc. (the “Company”) of his decision to resign as a member of the Board of Directors of the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818794/000095017023024258/0000950170-23-024258-index.htm
- Shareholder Votes
  Dyne Therapeutics, Inc. shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-05-24 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-05-24
  source text: b) The stockholders of the Company ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The results of the stockholders’ vote with respect to such matter were as follows: For Against Abstain 44,199,721 2,413 3
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818794/000095017023024258/0000950170-23-024258-index.htm
- Shareholder Votes
  Dyne Therapeutics, Inc. shareholders approved Election of three Class III directors: Joshua Brumm, David Lubner, and Jason Rhodes at the 2023-05-24 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-05-24
  source text: The stockholders of the Company elected Joshua Brumm, David Lubner and Jason Rhodes as Class III directors, each to serve for a three-year term expiring at the 2026 annual meeting of stockholders and until his respective successor has been duly elected and qualified. The results of the stockholders’ vote with respect to such matter were as follows: Name For Withheld Broker Non-Votes Joshua Brumm 35,497,922 6,780,619 1,923,596 David Lubner 32,530,452 9,748,089 1,923,596 Jason Rhodes 28,522,828 13,755,713 1,923,596
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818794/000095017023024258/0000950170-23-024258-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.